Drugging the undruggable: early phase trial shows trabectedin and low-dose irinotecan downregulate EWSR1::FLI1 and has clinical activity in advanced Ewing sarcoma

Trends in Cancer · Elsevier

Аннотация

Publication date: October 2026 Source: Trends in Cancer, Volume 12, Issue 10 Author(s): David S. Shulman, Katherine A. Janeway

Читать у издателя →

Похожие статьи